从特应性皮炎发病机制谈靶向治疗进展

doi:10.35541/cjd.20230054

中华皮肤科杂志 ›› 2023, Vol. 56 ›› Issue (8): 718-723.doi: 10.35541/cjd.20230054

从特应性皮炎发病机制谈靶向治疗进展

宋志强陈奇权葛兰

陆军军医大学西南医院皮肤科，重庆 400038

收稿日期:2023-02-06 修回日期:2023-05-21 发布日期:2023-08-07
通讯作者: 宋志强 E-mail:zhiqiang.song@hotmail.com
基金资助:
国家自然科学基金（82273529）

Insights into the progress in targeted therapy of atopic dermatitis from the perspective of its pathogenesis

Song Zhiqiang, Chen Qiquan, Ge Lan

Department of Dermatology, Southwest Hospital, Army Medical University, Chongqing 400038, China

Received:2023-02-06 Revised:2023-05-21 Published:2023-08-07
Contact: Song Zhiqiang E-mail:zhiqiang.song@hotmail.com
Supported by:
National Natural Science Foundation of China（82273529）

摘要/Abstract

摘要： 【摘要】特应性皮炎的发病机制复杂，主要与遗传背景、环境刺激、表皮屏障缺陷、免疫失调等因素有关。以Th2型炎症细胞因子以及JAK-STAT通路作为治疗靶点已成为特应性皮炎药物开发的热点。目前已有多个生物制剂和小分子药物成功用于特应性皮炎的治疗，标志其治疗已经迈入精准治疗和靶向治疗时代。

关键词: 皮炎, 特应性, 分子靶向治疗, 生物制剂, Janus激酶类, 发病机制, 精准治疗

Abstract: 【Abstract】 The pathogenesis of atopic dermatitis is complex, and mainly related to genetic background, environmental stimuli, epidermal barrier defects, immune disorders, and other factors. Using Th2-type inflammatory cytokines and the JAK-STAT pathway as therapeutic targets has become a hotspot in drug development for atopic dermatitis. By now, multiple monoclonal antibodies and small-molecule drugs have been successfully used in the treatment of atopic dermatitis, marking that the treatment of atopic dermatitis has entered the era of precision therapy and targeted therapy.

Key words: Dermatitis, atopic, Molecular targeted therapy, Biological agents, Janus kinases, Pathogenesis, Precision therapy

宋志强陈奇权葛兰. 从特应性皮炎发病机制谈靶向治疗进展[J]. 中华皮肤科杂志, 2023,56(8):718-723. doi:10.35541/cjd.20230054

Song Zhiqiang, Chen Qiquan, Ge Lan. Insights into the progress in targeted therapy of atopic dermatitis from the perspective of its pathogenesis [J]. Chinese Journal of Dermatology, 2023, 56(8): 718-723.doi:10.35541/cjd.20230054

参考文献 37

［1］	Laughter MR, Maymone M, Mashayekhi S, et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990-2017［J］. Br J Dermatol, 2021,184（2）:304⁃309. doi: 10.1111/bjd.19580.
［2］	Sacotte R, Silverberg JI. Epidemiology of adult atopic dermatitis［J］. Clin Dermatol, 2018,36（5）:595⁃605. doi: 10.1016/j.clindermatol.2018.05.007.
［3］	Birdi G, Cooke R, Knibb RC. Impact of atopic dermatitis on quality of life in adults: a systematic review and meta⁃analysis［J］. Int J Dermatol, 2020,59（4）:e75⁃e91. doi: 10.1111/ijd.14763.
［4］	Li W, Man XY. Immunotherapy in atopic dermatitis［J］. Immunotherapy, 2022,14（14）:1149⁃1164. doi: 10.2217/imt⁃2022⁃0054.
［5］	Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease［J］. Nat Rev Drug Discov, 2022,21（1）:21⁃40. doi: 10.1038/s41573⁃021⁃00266⁃6.
［6］	Gandhi NA, Bennett BL, Graham NM, et al. Targeting key proximal drivers of type 2 inflammation in disease［J］. Nat Rev Drug Discov, 2016,15（1）:35⁃50. doi: 10.1038/nrd4624.
［7］	Awosika O, Kim L, Mazhar M, et al. Profile of dupilumab and its potential in the treatment of inadequately controlled moderate⁃to⁃severe atopic dermatitis［J］. Clin Cosmet Investig Dermatol, 2018,11:41⁃49. doi: 10.2147/CCID.S123329.
［8］	Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis［J］. J Allergy Clin Immunol, 2021,148（4）:927⁃940. doi: 10.1016/j.jaci.2021.08.009.
［9］	Harb H, Chatila TA. Mechanisms of dupilumab［J］. Clin Exp Allergy, 2020,50（1）:5⁃14. doi: 10.1111/cea.13491.
［10］	Simpson EL, Bieber T, Guttman⁃Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis［J］. N Engl J Med, 2016,375（24）:2335⁃2348. doi: 10.1056/NEJMoa 1610020.
［11］	Thaçi D, L Simpson E, Deleuran M, et al. Efficacy and safety of dupilumab monotherapy in adults with moderate⁃to⁃severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials （LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2）［J］. J Dermatol Sci, 2019,94（2）:266⁃275. doi: 10.1016/j.jdermsci. 2019.02.002.
［12］	Beck LA, Deleuran M, Bissonnette R, et al. Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open⁃label study of adults with moderate⁃to⁃severe atopic dermatitis［J］. Am J Clin Dermatol, 2022,23（3）:393⁃408. doi: 10.1007/s40257⁃022⁃00685⁃0.
［13］	Cork MJ, Thaçi D, Eichenfield LF, et al. Dupilumab provides favourable long⁃term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open⁃label phase IIa study and subsequent phaseⅢ open⁃label extension study［J］. Br J Dermatol, 2021,184（5）:857⁃870. doi: 10.1111/bjd.19460.
［14］	Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double⁃blind, placebo⁃controlled, phase 3 trial［J］. Lancet, 2022,400（10356）:908⁃919. doi: 10. 1016/S0140⁃6736（22）01539⁃2.
［15］	Jo CE, Finstad A, Georgakopoulos JR, et al. Facial and neck erythema associated with dupilumab treatment: a systematic review［J］. J Am Acad Dermatol, 2021,84（5）:1339⁃1347. doi: 10.1016/j.jaad.2021.01.012.
［16］	Akinlade B, Guttman⁃Yassky E, de Bruin⁃Weller M, et al. Conjunctivitis in dupilumab clinical trials［J］. Br J Dermatol, 2019,181（3）:459⁃473. doi: 10.1111/bjd.17869.
［17］	Papp KA, Hong CH, Lansang MP, et al. Practical management of patients with atopic dermatitis on dupilumab［J］. Dermatol Ther （Heidelb）, 2021,11（5）:1805⁃1828. doi: 10.1007/s13555⁃021⁃00586⁃w.
［18］	Wollenberg A, Blauvelt A, Guttman⁃Yassky E, et al. Tralokinumab for moderate⁃to⁃severe atopic dermatitis: results from two 52⁃week, randomized, double⁃blind, multicentre, placebo⁃controlled phaseⅢ trials （ECZTRA 1 and ECZTRA 2）［J］. Br J Dermatol, 2021,184（3）:437⁃449. doi: 10.1111/bjd. 19574.
［19］	Silverberg JI, Guttman⁃Yassky E, Thaçi D, et al. Two phase 3 trials of lebrikizumab for moderate⁃to⁃severe atopic dermatitis［J］. N Engl J Med, 2023,388（12）:1080⁃1091. doi: 10.1056/NEJMoa2206714.
［20］	Kabashima K, Matsumura T, Komazaki H, et al. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus［J］. N Engl J Med, 2020,383（2）:141⁃150. doi: 10.1056/NEJMoa1917006.
［21］	Guttman⁃Yassky E, Brunner PM, Neumann AU, et al. Efficacy and safety of fezakinumab （an IL⁃22 monoclonal antibody） in adults with moderate⁃to⁃severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double⁃blind, phase 2a trial［J］. J Am Acad Dermatol, 2018,78（5）:872⁃881.e6. doi: 10.1016/j.jaad.2018.01.016.
［22］	Chen YL, Gutowska⁃Owsiak D, Hardman CS, et al. Proof⁃of⁃concept clinical trial of etokimab shows a key role for IL⁃33 in atopic dermatitis pathogenesis［J］. Sci Transl Med, 2019,11（515）:eaax2945. doi: 10.1126/scitranslmed.aax2945.
［23］	Guttman⁃Yassky E, Pavel AB, Zhou L, et al. GBR 830, an anti⁃OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis［J］. J Allergy Clin Immunol, 2019,144（2）:482⁃493.e7. doi: 10.1016/j.jaci.2018.11.053.
［24］	Bao L, Zhang H, Chan LS. The involvement of the JAK⁃STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis［J］. JAKSTAT, 2013,2（3）:e24137. doi: 10.4161/jkst. 24137.
［25］	Le M, Berman⁃Rosa M, Ghazawi FM, et al. Systematic review on the efficacy and safety of oral janus kinase inhibitors for the treatment of atopic dermatitis［J］. Front Med （Lausanne）, 2021,8:682547. doi: 10.3389/fmed.2021.682547.
［26］	Guttman⁃Yassky E, Teixeira HD, Simpson EL, et al. Once⁃daily upadacitinib versus placebo in adolescents and adults with moderate⁃to⁃severe atopic dermatitis （Measure Up 1 and Measure Up 2）: results from two replicate double⁃blind, randomised controlled phase 3 trials［J］. Lancet, 2021,397（10290）:2151⁃2168. doi: 10.1016/S0140⁃6736（21）00588⁃2.
［27］	Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate⁃to⁃severe atopic dermatitis （JADE MONO⁃1）: a multicentre, double⁃blind, randomised, placebo⁃controlled, phase 3 trial［J］. Lancet, 2020,396（10246）:255⁃266. doi: 10.1016/S0140⁃6736（20）30732⁃ 7.
［28］	Ständer S, Bhatia N, Gooderham MJ, et al. High threshold efficacy responses in moderate⁃to⁃severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents［J］. J Eur Acad Dermatol Venereol, 2022,36（8）:1308⁃1317. doi: 10.1111/jdv.18170.
［29］	Simpson EL, Forman S, Silverberg JI, et al. Baricitinib in patients with moderate⁃to⁃severe atopic dermatitis: results from a randomized monotherapy phase 3 trial in the United States and Canada （BREEZE⁃AD5）［J］. J Am Acad Dermatol, 2021,85（1）:62⁃70. doi: 10.1016/j.jaad.2021.02.028.
［30］	Nakagawa H, Nemoto O, Igarashi A, et al. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double⁃blind, vehicle⁃controlled study and an open⁃label, long⁃term extension study［J］. J Am Acad Dermatol, 2020,82（4）:823⁃831. doi: 10.1016/j.jaad.2019.12.015.
［31］	Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double⁃blind studies［J］. J Am Acad Dermatol, 2021,85（4）:863⁃872. doi: 10.1016/j.jaad.2021. 04.085.
［32］	Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 （PDE4） inhibitor for the topical treatment of atopic dermatitis （AD） in children and adults［J］. J Am Acad Dermatol, 2016,75（3）:494⁃503.e6. doi: 10.1016/j.jaad.2016.05.046.
［33］	Reich K, Thyssen JP, Blauvelt A, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate⁃to⁃severe atopic dermatitis: a randomised, double⁃blind, multicentre phase 3 trial［J］. Lancet, 2022,400（10348）:273⁃282. doi: 10.1016/S0140⁃6736（22）01199⁃0.
［34］	Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate⁃to⁃severe atopic dermatitis: a randomized clinical trial［J］. JAMA Dermatol, 2021,157（9）:1047⁃1055. doi: 10.1001/jamadermatol.2021.3023.
［35］	Drucker AM, Morra DE, Prieto⁃Merino D, et al. Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta⁃analysis［J］. JAMA Dermatol, 2022,158（5）:523⁃532. doi: 10.1001/jamadermatol.2022. 0455.
［36］	Lin CM, Cooles FA, Isaacs JD. Basic mechanisms of JAK inhibition［J］. Mediterr J Rheumatol, 2020,31（Suppl 1）:100⁃104. doi: 10.31138/mjr.31.1.100.
［37］	Makhoba XH, Viegas C Jr, Mosa RA, et al. Potential impact of the multi⁃target drug approach in the treatment of some complex diseases［J］. Drug Des Devel Ther, 2020,14:3235⁃3249. doi: 10.2147/DDDT.S257494.

[1]	刘小扬赵琰蔡林张建中. 银屑病患者白细胞介素17拮抗剂治疗后出现特应性皮炎样皮疹4例分析与文献回顾[J]. 中华皮肤科杂志, 2023, 56(9): 845-848.
[2]	郭昊刘辉张丽朱冠男王平姚志荣高兴华陈耀龙. 特应性皮炎诊疗指南（专科医生版本、全科医生版本和患者版本）计划书[J]. 中华皮肤科杂志, 2023, 56(9): 809-814.
[3]	陈春里闫思聿王丹高丽华谭丽娜唐四元刘伟曾金容鲁建云. 酸化脂肪酸酯治疗特应性皮炎样模型小鼠的疗效及机制初探[J]. 中华皮肤科杂志, 2023, 56(9): 822-831.
[4]	王珊王星宇舒虹张斌石航杨欢钱秋芳马红艳梁源赵牧童申春平焦磊田晶汪洋谷盈孙婧刘盈李萍王华马琳. 克立硼罗软膏早期缓解儿童特应性皮炎临床症状及改善缓解期临床症状的多中心临床研究[J]. 中华皮肤科杂志, 2023, 56(9): 815-821.
[5]	周彤耿松梅. 生物制剂在大疱性类天疱疮治疗中的应用[J]. 中华皮肤科杂志, 2023, 56(8): 789-793.
[6]	申春平李萍罗晓燕梁源刘盈赵牧童王珊田晶焦磊汪洋罗珍余时娟方晓王华马琳. [开放获取] 某润肤霜联合周末外用糖皮质激素对延缓儿童特应性皮炎维持期疾病复发的随机、空白对照、多中心临床研究[J]. 中华皮肤科杂志, 2023, 56(8): 756-762.
[7]	徐西利李东宁段函王菲. 青少年及成人特应性皮炎患者血浆氨基酸代谢水平分析[J]. 中华皮肤科杂志, 2023, 56(8): 742-750.
[8]	张晓东汪蔓雅朱英杰骆天德刘小明. 荧光染色法在面部皮肤蠕形螨检查中的应用评估[J]. 中华皮肤科杂志, 2023, 56(8): 766-769.
[9]	渠莉田陈锦丛程波苏惠春. 特应性皮炎患者外周血单个核细胞转谷氨酰胺酶2的表达与相关炎症因子及疾病严重程度的相关性[J]. 中华皮肤科杂志, 2023, 56(7): 651-656.
[10]	蒋晓妍高敏张晓艳刘宁远. 白细胞介素17和白细胞介素23拮抗剂治疗脓疱型银屑病研究进展[J]. 中华皮肤科杂志, 2023, 56(7): 689-692.
[11]	梁云生黎展宏伍奕蓓. [开放获取] 从发病机制认知变化看慢性自发性荨麻疹治疗进展[J]. 中华皮肤科杂志, 2023, 56(6): 552-558.
[12]	杨娜丽许秋阳吴含文叶雅慧朱吉玲刘晶晶李智铭. [开放获取] 奥马珠单抗治疗慢性荨麻疹的疗效和安全性回顾性分析[J]. 中华皮肤科杂志, 2023, 56(6): 518-524.
[13]	陈奇权孔敏敏杨显杰王欢李健张名望宋志强. [开放获取] 慢性诱导性荨麻疹患者168例过敏原反应性和特应性病史的临床分析[J]. 中华皮肤科杂志, 2023, 56(6): 496-503.
[14]	苏畅隋秀丽刘瑞玲曹毅群姜虹严彩蓉王惠平亓玉青. [开放获取] 奥马珠单抗治疗慢性自发性荨麻疹伴有其他过敏性疾病患者74例临床分析[J]. 中华皮肤科杂志, 2023, 56(6): 512-517.
[15]	李丽俏彭聪陈翔李捷. [开放获取] 奥马珠单抗治疗对抗组胺药反应不佳的慢性荨麻疹患者单中心回顾性研究[J]. 中华皮肤科杂志, 2023, 56(6): 504-511.

从特应性皮炎发病机制谈靶向治疗进展

Insights into the progress in targeted therapy of atopic dermatitis from the perspective of its pathogenesis

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 37

相关文章 15

Metrics

本文评价

推荐阅读 10